TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
Stocks · News reference
8-K filing — ANAPTYSBIO, INC (ANAB)
Filed: 2026-06-22 AccNo: 0001193125-26-277505 Size: 151 KB Item 1.01: Entry into a Material Definitive Agreement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.